COL6A1 (Collagen alpha-1(VI) chain) variants and mutations
COL6A1 (also known as Collagen alpha-1(VI) chain) is a human protein-coding gene encoding a collagen alpha-1(VI) chain protein. It contributes to extracellular microfibrils that connect cells with surrounding matrix and are especially important in skeletal muscle and connective tissue. Pathogenic variants can cause collagen VI-related myopathies ranging from Bethlem muscular dystrophy to severe Ullrich congenital muscular dystrophy. This analysis covers 1,705 COL6A1 variants and mutations. Of these, 87% have computational variant effect predictions. Disease context includes Bethlem myopathy 1A, Ullrich congenital muscular dystrophy 1A, and Bethlem myopathy. Example COL6A1 variants include M1L, R2K, and R2M.
Variant analysis overview
- Gene: COL6A1
- Protein: Collagen alpha-1(VI) chain
- UniProt accession: P12109
- Organism: Homo sapiens
- Variants analyzed: 1705
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 1,467 unspecified-consequence records; 14 frameshift variants; 119 missense variants; 90 synonymous variants; 3 in-frame deletions; 9 stop-gained variants; 3 splice-region variants
- Prediction scores: 1,480 variants have prediction scores (87% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Bethlem myopathy 1A, Ullrich congenital muscular dystrophy 1A, Bethlem myopathy, Congenital muscular dystrophy, Ullrich type, collagen 6-related myopathy, Dupuytren Contracture, hereditary disease, diverticular disease, Abnormality of the musculature, Skin ulcer, myopathy, eye disorder.
Protein structure and variant hotspots
- Protein features: 3 domains; 5 post-translational modification sites.
- Structural context: 970 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable COL6A1 variants
Examples include M1L, R2K, R2M, R2G, R2T, A3G, A3V, A3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1L (p.Met1Leu), rs2123459059, ClinGen CA410513700, ClinVar RCV002036299, MetaLR 0.49, MetaSVM -0.12, Uncertain significance, Bethlem myopathy 1A
- R2K (p.Arg2Lys), rs1305504243, ClinGen CA410513724, ClinVar RCV000700263, gnomAD rs1305504243, REVEL 0.16, CADD 10.20, Uncertain significance, Bethlem myopathy 1A
- R2M (p.Arg2Met), NCI-TCGA TCGA novel, REVEL 0.28, CADD 19.10, Variant assessed as somatic; moderate impact.
- R2G (p.Arg2Gly), gnomAD 21-45981854-A-G, REVEL 0.22, MetaLR 0.40
- R2T (p.Arg2Thr), gnomAD 21-45981855-G-C, REVEL 0.11, MetaLR 0.38
- A3G (p.Ala3Gly), TOPMed rs1364376797
- A3V (p.Ala3Val), TOPMed rs1364376797, REVEL 0.14, CADD 10.20, Uncertain significance, Bethlem myopathy 1A
- A3R (p.Ala3Arg), gnomAD 21-45981854-AG-A, CADD 22.10
- A3S (p.Ala3Ser), gnomAD 21-45981857-G-T, REVEL 0.16, MetaLR 0.36
- A3P (p.Ala3Pro), gnomAD 21-45981857-G-C, REVEL 0.13, MetaLR 0.39
- A3E (p.Ala3Glu), gnomAD 21-45981858-C-A, REVEL 0.14, MetaLR 0.38
- A3A (p.Ala3Ala), rs369561233, gnomAD 21-45981859-G-A, CADD 10.60
- A4T (p.Ala4Thr), rs1603589147, ClinGen CA410513763, ClinVar RCV001884889, Ensembl rs1603589147, REVEL 0.18, CADD 13.20, Uncertain significance, Bethlem myopathy 1A
- A4S (p.Ala4Ser), gnomAD 21-45981860-G-T, REVEL 0.15, MetaLR 0.40
- A4P (p.Ala4Pro), gnomAD 21-45981860-G-C, REVEL 0.23, MetaLR 0.44
- A4D (p.Ala4Asp), gnomAD 21-45981861-C-A, REVEL 0.20, MetaLR 0.41
- A4V (p.Ala4Val), gnomAD 21-45981861-C-T, REVEL 0.13, MetaLR 0.40
- A4A (p.Ala4Ala), gnomAD 21-45981862-C-A, CADD 9.57
- R5C (p.Arg5Cys), rs1235513102, ClinGen CA410513780, ClinVar RCV001864732, TOPMed rs1235513102, REVEL 0.18, CADD 11.70, Uncertain significance, Bethlem myopathy 1A
- R5H (p.Arg5His), rs1556423460, ClinGen CA410513782, ClinVar RCV000531376, Ensembl rs1556423460, REVEL 0.18, CADD 7.72, Uncertain significance, Bethlem myopathy 1A
- R5V (p.Arg5Val), gnomAD 21-45981860-GC-G, CADD 21.70
- R5S (p.Arg5Ser), gnomAD 21-45981863-C-A, REVEL 0.14, MetaLR 0.37
- R5G (p.Arg5Gly), gnomAD 21-45981863-C-G, REVEL 0.16, MetaLR 0.38
- R5L (p.Arg5Leu), gnomAD 21-45981864-G-T, REVEL 0.14, MetaLR 0.41
- R5R (p.Arg5Arg), rs2123459083, gnomAD 21-45981865-T-A, CADD 4.80
- A6G (p.Ala6Gly), rs2526305354, ClinGen CA410513794, ClinVar RCV002861644, REVEL 0.25, CADD 8.10, Uncertain significance, Bethlem myopathy 1A
- A6P (p.Ala6Pro), TOPMed rs2077708924, REVEL 0.30, CADD 4.35
- A6T (p.Ala6Thr), gnomAD 21-45981866-G-A, REVEL 0.12, MetaLR 0.41
- A6S (p.Ala6Ser), gnomAD 21-45981866-G-T, REVEL 0.07, MetaLR 0.41
- A6V (p.Ala6Val), gnomAD 21-45981867-C-T, REVEL 0.14, MetaLR 0.41
- A6D (p.Ala6Asp), gnomAD 21-45981867-C-A, REVEL 0.19, MetaLR 0.42
- A6A (p.Ala6Ala), gnomAD 21-45981868-T-C, CADD 10.20
- L7M (p.Leu7Met), rs1280132890, ClinGen CA410513800, ClinVar RCV003018142, TOPMed rs1280132890, REVEL 0.33, CADD 23.00, Uncertain significance, Bethlem myopathy 1A
- L7L (p.Leu7Leu), rs1280132890, gnomAD 21-45981869-C-T, CADD 10.60
- L8P (p.Leu8Pro), 1000Genomes rs543400339, ExAC rs543400339, gnomAD rs543400339, REVEL 0.59, CADD 22.90
- L8M (p.Leu8Met), gnomAD 21-45981872-C-A, REVEL 0.24, MetaLR 0.43
- L8L (p.Leu8Leu), gnomAD 21-45981872-C-T, CADD 11.80
- P9L (p.Pro9Leu), 1000Genomes rs561566597, gnomAD rs561566597, REVEL 0.24, CADD 14.20
- P9S (p.Pro9Ser), NCI-TCGA TCGA novel, REVEL 0.17, CADD 12.00, Variant assessed as somatic; moderate impact.
- P9T (p.Pro9Thr), gnomAD 21-45981875-C-A, REVEL 0.23, MetaLR 0.34
- P9P (p.Pro9Pro), gnomAD 21-45981877-C-A, CADD 10.70
- L10R (p.Leu10Arg), Ensembl rs1603589155
- L10A (p.Leu10Ala), gnomAD 21-45981874-GCC-G, CADD 22.90
- L10L (p.Leu10Leu), rs770938233, gnomAD 21-45981878-C-T, CADD 12.30
- L10M (p.Leu10Met), gnomAD 21-45981878-C-A, REVEL 0.32, MetaLR 0.60
- L10P (p.Leu10Pro), gnomAD 21-45981879-T-C, REVEL 0.73, MetaLR 0.59
- p.Leu11 Cys15del, gnomAD 21-45981879-TGCTG, CADD 19.60
- L11M (p.Leu11Met), gnomAD 21-45981881-C-A, REVEL 0.40, MetaLR 0.64
- L11L (p.Leu11Leu), gnomAD 21-45981881-C-T, CADD 13.80
- L12del (p.Leu12del), gnomAD 21-45981877-CCTG-, CADD 19.40
- L12L (p.Leu12Leu), rs1273801694, gnomAD 21-45981884-C-T, CADD 11.70
- L12P (p.Leu12Pro), gnomAD 21-45981885-T-C, REVEL 0.67, MetaLR 0.54
- Q13* (p.Gln13Ter), gnomAD 21-45981887-C-T, CADD 36.00
- Q13K (p.Gln13Lys), gnomAD 21-45981887-C-A, REVEL 0.35, MetaLR 0.31
- Q13H (p.Gln13His), gnomAD 21-45981889-G-T, REVEL 0.38, MetaLR 0.47
- A14T (p.Ala14Thr), rs1454397058, ClinGen CA410513877, ClinVar RCV001920020, TOPMed rs1454397058, REVEL 0.34, CADD 23.90, Uncertain significance, Bethlem myopathy 1A
- A14S (p.Ala14Ser), gnomAD 21-45981890-G-T, REVEL 0.31, MetaLR 0.43
- A14P (p.Ala14Pro), gnomAD 21-45981890-G-C, REVEL 0.56, MetaLR 0.55
- A14V (p.Ala14Val), gnomAD 21-45981891-C-T, REVEL 0.34, MetaLR 0.47
- A14D (p.Ala14Asp), gnomAD 21-45981891-C-A, REVEL 0.60, MetaLR 0.55
- A14A (p.Ala14Ala), rs1176083983, gnomAD 21-45981892-C-T, CADD 13.20
- C15F (p.Cys15Phe), rs776678940, ClinGen CA10069426, ClinVar RCV003044526, ExAC rs776678940, REVEL 0.49, CADD 22.10, Uncertain significance, Bethlem myopathy 1A
- C15R (p.Cys15Arg), rs2526305434, NCI-TCGA Cosmic COSV6261, cosmic curated COSV62614, ClinGen CA410513885, Uncertain significance, not provided
- C15Y (p.Cys15Tyr), gnomAD 21-45981894-G-A, REVEL 0.43, MetaLR 0.46
- W16C (p.Trp16Cys), NCI-TCGA TCGA novel, Ensembl rs2077709127, REVEL 0.62, CADD 24.30, Variant assessed as somatic; moderate impact.
- W16R (p.Trp16Arg), rs760101861, ClinGen CA10069427, ClinVar RCV003631422, ClinVar RCV004786986, REVEL 0.62, CADD 26.50, Conflicting interpretations, Ullrich congenital muscular dystrophy 1A; Bethlem myopathy 1A
- T17S (p.Thr17Ser), rs747419878, gnomAD 21-45981898-GAC-G, CADD 22.80
- T17I (p.Thr17Ile), gnomAD 21-45981900-C-T, REVEL 0.14, MetaLR 0.37
- A18V (p.Ala18Val), TOPMed rs1394319780, gnomAD rs1394319780, REVEL 0.15, CADD 13.20
- A18T (p.Ala18Thr), gnomAD 21-45981902-G-A, REVEL 0.14, MetaLR 0.37
- A18S (p.Ala18Ser), gnomAD 21-45981902-G-T, REVEL 0.15, MetaLR 0.32
- A18D (p.Ala18Asp), gnomAD 21-45981903-C-A, REVEL 0.18, MetaLR 0.46
- A18A (p.Ala18Ala), gnomAD 21-45981904-C-T, CADD 7.57
- A19P (p.Ala19Pro), gnomAD rs1212976682, REVEL 0.32, CADD 12.50
- A19V (p.Ala19Val), cosmic curated COSV62612, gnomAD rs1412528374
- A19S (p.Ala19Ser), gnomAD 21-45981905-G-T, REVEL 0.10, MetaLR 0.37
- A19T (p.Ala19Thr), gnomAD 21-45981905-G-A, REVEL 0.10, MetaLR 0.38
- A19E (p.Ala19Glu), gnomAD 21-45981906-C-A, REVEL 0.16, MetaLR 0.38
- A19A (p.Ala19Ala), gnomAD 21-45981907-G-T, CADD 1.34
- Q20* (p.Gln20Ter), rs1603589167, ClinGen CA410513938, ClinVar RCV000804162, Ensembl rs1603589167, Pathogenic
- Q20R (p.Gln20Arg), gnomAD rs1355261455, REVEL 0.28, CADD 19.10
- Q20K (p.Gln20Lys), gnomAD 21-45981908-C-A, REVEL 0.37, MetaLR 0.36
- D21H (p.Asp21His), rs1421011932, ClinGen CA410513960, ClinVar RCV003632494, ClinVar RCV005545081, REVEL 0.37, CADD 23.80, Uncertain significance, Inborn genetic diseases; Bethlem myopathy 1A
- D21N (p.Asp21Asn), gnomAD 21-45981911-G-A, REVEL 0.21, MetaLR 0.40
- D21Y (p.Asp21Tyr), gnomAD 21-45981911-G-T, REVEL 0.48, MetaLR 0.52
- E22K (p.Glu22Lys), rs1461577118, ClinGen CA410513978, ClinVar RCV001321234, gnomAD rs1461577118, REVEL 0.24, CADD 0.60, Likely benign, Bethlem myopathy 1A
- E22* (p.Glu22Ter), gnomAD 21-45981914-G-T, CADD 27.20
- E22V (p.Glu22Val), gnomAD 21-45981915-A-T, REVEL 0.17, MetaLR 0.40
- P23L (p.Pro23Leu), rs775946362, ClinGen CA10069430, ClinVar RCV001217320, ClinVar RCV002561922, REVEL 0.13, CADD 5.79, Conflicting interpretations, Inborn genetic diseases; Bethlem myopathy 1A
- P23T (p.Pro23Thr), ExAC rs770178435, gnomAD rs770178435, REVEL 0.10, CADD 6.01
- P23S (p.Pro23Ser), gnomAD 21-45981917-C-T, REVEL 0.11, MetaLR 0.34
- P23Q (p.Pro23Gln), gnomAD 21-45981918-C-A, REVEL 0.11, MetaLR 0.32
- P23P (p.Pro23Pro), rs149741299, gnomAD 21-45981919-G-A, CADD 1.88
- E24G (p.Glu24Gly), gnomAD 21-45981921-A-G, REVEL 0.16, MetaLR 0.38
- E24V (p.Glu24Val), gnomAD 21-45981921-A-T, REVEL 0.21, MetaLR 0.34
- E24D (p.Glu24Asp), gnomAD 21-45981922-G-T, REVEL 0.19, MetaLR 0.41
- T25N (p.Thr25Asn), rs767205402, ClinGen CA10069432, ClinVar RCV000338991, ClinVar RCV002518061, REVEL 0.13, CADD 0.30, Conflicting interpretations, not provided; Bethlem myopathy 1A
- P26L (p.Pro26Leu), rs150165253, ClinGen CA10069433, ClinVar RCV003145755, ClinVar RCV006473703, REVEL 0.23, CADD 12.00, Conflicting interpretations, Bethlem myopathy 1A; not provided
- P26T (p.Pro26Thr), NCI-TCGA Cosmic COSV6261, cosmic curated COSV62611, MetaLR 0.32, MetaSVM -0.71, Variant assessed as somatic; moderate impact.
- P26R (p.Pro26Arg), gnomAD 21-45981923-AC-A, CADD 13.70
- P26Q (p.Pro26Gln), gnomAD 21-45981927-C-A, REVEL 0.15, MetaLR 0.38
- P26P (p.Pro26Pro), gnomAD 21-45981928-G-T, CADD 0.99
- R27G (p.Arg27Gly), TOPMed rs1031520613, gnomAD rs1031520613, REVEL 0.18, CADD 18.60, Uncertain significance
- R27S (p.Arg27Ser), TOPMed rs2077709388, REVEL 0.26, CADD 11.20, Uncertain significance, Inborn genetic diseases
- R27W (p.Arg27Trp), rs1031520613, ClinGen CA410514066, ClinVar RCV001334957, TOPMed rs1031520613, REVEL 0.29, CADD 24.00, Uncertain significance, Ullrich congenital muscular dystrophy 1A
- R27K (p.Arg27Lys), gnomAD 21-45981930-G-A, REVEL 0.09, MetaLR 0.33
- A28T (p.Ala28Thr), gnomAD rs1274682105, REVEL 0.09, CADD 14.40
- A28V (p.Ala28Val), rs2526305516, ClinGen CA410514094, ClinVar RCV002667036, REVEL 0.15, CADD 13.60, Uncertain significance, Bethlem myopathy 1A
- A28S (p.Ala28Ser), gnomAD 21-45981932-G-T, REVEL 0.18, MetaLR 0.39
- A28D (p.Ala28Asp), gnomAD 21-45981933-C-A, REVEL 0.26, MetaLR 0.41
- A28A (p.Ala28Ala), gnomAD 21-45981934-C-A, CADD 5.41
- V29M (p.Val29Met), rs766057159, ClinGen CA10069435, ClinVar RCV000689329, ClinVar RCV003144500, REVEL 0.24, CADD 12.50, Uncertain significance, Inborn genetic diseases; not provided; Bethlem myopathy 1A
- V29L (p.Val29Leu), gnomAD 21-45981935-G-T, REVEL 0.15, MetaLR 0.36
- V29V (p.Val29Val), gnomAD 21-45981937-G-T, CADD 2.99
- A30S (p.Ala30Ser), gnomAD 21-45981938-G-T, REVEL 0.27, MetaLR 0.45
- A30T (p.Ala30Thr), gnomAD 21-45981938-G-A, REVEL 0.22, MetaLR 0.42
- A30D (p.Ala30Asp), gnomAD 21-45981939-C-A, REVEL 0.30, MetaLR 0.53
- A30V (p.Ala30Val), gnomAD 21-45981939-C-T, REVEL 0.33, MetaLR 0.47
- F31L (p.Phe31Leu), rs753371577, ClinGen CA410514160, ClinVar RCV003145732, ExAC rs753371577, REVEL 0.44, CADD 22.60, Uncertain significance, not provided
- F31S (p.Phe31Ser), TOPMed rs1255649743, gnomAD rs1255649743, REVEL 0.47, CADD 23.50
- F31F (p.Phe31Phe), rs753371577, gnomAD 21-45981943-C-T, CADD 13.30
- Q32* (p.Gln32Ter), TOPMed rs1194246077, gnomAD rs1194246077, CADD 37.00
- Q32H (p.Gln32His), NCI-TCGA TCGA novel, REVEL 0.46, CADD 21.90, Uncertain significance, Bethlem myopathy 1A
- Q32K (p.Gln32Lys), gnomAD 21-45981944-C-A, REVEL 0.45, MetaLR 0.73
- Q32R (p.Gln32Arg), gnomAD 21-45981945-A-G, REVEL 0.41, MetaLR 0.78
- Q32Q (p.Gln32Gln), rs754988212, gnomAD 21-45981946-G-A, CADD 8.89
- D33Y (p.Asp33Tyr), TOPMed rs1310676059, REVEL 0.72, CADD 33.00
- C34F (p.Cys34Phe), rs756091850, ClinGen CA10069464, ClinVar RCV001228336, ExAC rs756091850, REVEL 0.85, CADD 32.00, Likely benign, Bethlem myopathy 1A
- C34C (p.Cys34Cys), rs373972331, gnomAD 21-45982638-C-T, CADD 14.90
- P35H (p.Pro35His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P35L (p.Pro35Leu), Ensembl rs2077714483
- P35S (p.Pro35Ser), TOPMed rs2077714471, MetaLR 0.91, MetaSVM 0.90
- P35P (p.Pro35Pro), rs145579577, gnomAD 21-45982641-C-T, CADD 6.51
- V36L (p.Val36Leu), cosmic curated COSV62614, ExAC rs769258891, TOPMed rs769258891, gnomAD rs769258891, REVEL 0.62, CADD 32.00, Likely benign
- V36M (p.Val36Met), rs769258891, ClinGen CA10069466, ClinVar RCV003061147, ExAC rs769258891, REVEL 0.65, CADD 32.00, Likely benign, Bethlem myopathy 1A
- V36V (p.Val36Val), rs1259912974, gnomAD 21-45982644-G-T, CADD 15.30
- D37N (p.Asp37Asn), gnomAD 21-45982645-G-A, REVEL 0.78, MetaLR 0.98
- D37D (p.Asp37Asp), rs774908764, gnomAD 21-45982647-C-T, CADD 14.90
- D37E (p.Asp37Glu), gnomAD 21-45982647-C-G, REVEL 0.75, MetaLR 0.97
- L38P (p.Leu38Pro), cosmic curated COSV62612, ExAC rs770741551, gnomAD rs770741551
- L38V (p.Leu38Val), ExAC rs748478347, gnomAD rs748478347, REVEL 0.41, CADD 22.80
- L38L (p.Leu38Leu), rs748478347, gnomAD 21-45982648-C-T, CADD 15.40
- L38M (p.Leu38Met), gnomAD 21-45982648-C-A, REVEL 0.59, MetaLR 0.70
- F39C (p.Phe39Cys), TOPMed rs2077714599, gnomAD rs2077714599, REVEL 0.76, CADD 33.00
- F39L (p.Phe39Leu), cosmic curated COSV10072, TOPMed rs767395722, gnomAD rs767395722, REVEL 0.36, CADD 24.10, Uncertain significance, Inborn genetic diseases; Bethlem myopathy 1A
- F39V (p.Phe39Val), NCI-TCGA Cosmic COSV6261, cosmic curated COSV62615, Variant assessed as somatic; moderate impact.
- F39Y (p.Phe39Tyr), gnomAD 21-45982652-T-A, REVEL 0.45, MetaLR 0.34
- V41E (p.Val41Glu), TOPMed rs1407806712, gnomAD rs1407806712, REVEL 0.96, CADD 32.00
- V41M (p.Val41Met), gnomAD rs1159664434, REVEL 0.85, CADD 32.00
- V41A (p.Val41Ala), gnomAD 21-45982658-T-C, REVEL 0.87, MetaLR 0.94
- V41V (p.Val41Val), rs148867790, gnomAD 21-45982659-G-A, CADD 14.00
- L42L (p.Leu42Leu), rs2077714658, gnomAD 21-45982660-C-T, CADD 15.10
- D43A (p.Asp43Ala), rs786205555, ClinGen CA236164, ClinVar RCV000171351, UniProt VAR 081097, AlphaMissense 1.00, MetaLR 0.95, Likely pathogenic, not provided
- D43Y (p.Asp43Tyr), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10072, NCI-TCGA Cosmic COSV6261, Uncertain significance
- D43N (p.Asp43Asn), gnomAD 21-45982663-G-A, REVEL 0.93, MetaLR 0.95
- D43D (p.Asp43Asp), rs1376425830, gnomAD 21-45982665-C-T, CADD 14.60
- T44A (p.Thr44Ala), gnomAD rs1296919343, REVEL 0.78, CADD 29.00
- T44S (p.Thr44Ser), rs2077714741, ClinGen CA410514541, ClinVar RCV001987112, TOPMed rs2077714741, REVEL 0.58, CADD 29.30, Uncertain significance, Bethlem myopathy 1A
- S45C (p.Ser45Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S45F (p.Ser45Phe), cosmic curated COSV10653, NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E46D (p.Glu46Asp), rs886043183, ClinGen CA10605210, ClinVar RCV000262300, TOPMed rs886043183, AlphaMissense 1.00, MetaLR 0.65, Uncertain significance, not provided
- E46G (p.Glu46Gly), TOPMed rs2077714794
- E46K (p.Glu46Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S47G (p.Ser47Gly), 1000Genomes rs2123460203
- S47R (p.Ser47Arg), rs1415065984, gnomAD 21-45982670-CTG-C, CADD 33.00
- S47S (p.Ser47Ser), rs2123460208, gnomAD 21-45982677-C-T, CADD 7.48
- V48L (p.Val48Leu), NCI-TCGA Cosmic COSV1007, NCI-TCGA Cosmic COSV6261, cosmic curated COSV62611, Variant assessed as somatic; moderate impact.
- V48M (p.Val48Met), gnomAD 21-45982678-G-A, REVEL 0.71, MetaLR 0.66
- V48V (p.Val48Val), rs1333093742, gnomAD 21-45982680-G-C, CADD 12.80
- A49S (p.Ala49Ser), gnomAD rs1338252132, REVEL 0.69, CADD 29.50
- A49G (p.Ala49Gly), gnomAD 21-45982682-C-G, REVEL 0.72, MetaLR 0.55
- A49V (p.Ala49Val), gnomAD 21-45982682-C-T, REVEL 0.78, MetaLR 0.69
- A49A (p.Ala49Ala), rs1443671437, gnomAD 21-45982683-C-A, CADD 11.80
- R51K (p.Arg51Lys), rs2526307426, ClinGen CA410514647, ClinVar RCV003480378, Uncertain significance, not provided
- R51S (p.Arg51Ser), gnomAD 21-45982687-AG-A, CADD 33.00
- R51R (p.Arg51Arg), rs200311716, gnomAD 21-45982689-G-A, CADD 15.20
- L52V (p.Leu52Val), gnomAD 21-45982690-C-G, REVEL 0.28, MetaLR 0.60
- K53N (p.Lys53Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K53R (p.Lys53Arg), Ensembl rs2077714984
- K53K (p.Lys53Lys), rs529266588, gnomAD 21-45982695-G-A, CADD 14.00
Public COL6A1 analysis runs
- COL6A1 analysis run — COL6A1 (1,705 variants) — completed 2026-08-21